Comparison of a 1.5T standard vs. 3T optimized protocols in multiple sclerosis patients

Minerva Medica

Volumn 103, Issue 2, 2012, Pages 97-102

  Livshits, I ^a   Hussein, S ^a   Kennedy, C ^a   Weinstock Guttman, B ^b   Hojnacki, D ^b   Zivadinov, R ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b JACOBS NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Gadolinium; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

GADOLINIUM PENTETATE;

1.5T STANDARDIZED IMAGING PROTOCOL; 3T OPTIMIZED IMAGING PROTOCOL; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING;

ADULT; CLINICAL PROTOCOLS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84862731819     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007;8:913-9.
2. Poser CM, Brinar VV. The nature of multiple sclerosis. Clin Neurol Neurosurg 2004;106:159-71.
3. Zivadinov R, Bakshi R. Role of MRI in multiple sclerosis I: inflammation and lesions. Front Biosci 2004;9:665-83.
4. Filippi M. Enhanced magnetic resonance imaging in multiple sclerosis. Mult Scler 2000;6:320-6.
5. Cotton F, Weiner HL, Jolesz FA, Guttmann CRG. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003;60:640-6.
6. Sicotte NL, Voskuhl RR, Bouvier S, Klutch R, Cohen MS, Mazziotta JC. Comparison of Multiple Sclerosis Lesions at 1.5 and 30 Tesla. Investigative Radiology 2003;38:423-7.
7. Weiner HL, Guttmann CRG, Khoury SJ, et al. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. J Neuroimmunol 2000;104:164-73.
8. Silver NC, Good CD, Sormani MP, MacManus DG, Thompson AJ, Filippi M et al. A modified protocol to improve the detection of enhancing brain and spinal cord leasions in multiple sclerosis. J Neurol 2001;248:215-24.
9. Filippi M, Rovaris M, Gasperini C, Capra R, Bastianello S, Kuhne I et al. A preliminary study comparing the sensitivity of serial monthly enhanced MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in primary progressive multiple sclerosis. J Neuroimaging 1998;8:88-93.
10. Barkhof F, Filippi M, van Waesberghe JH, Molyneux P, Rovaris M, Lycklama à Nijeholt G et al. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology 1997;49:1682-8.
11. Erskine MK, Cook LL, Riddle KE, Mitchell JR, Karlik SJ. Resolution-dependent estimates of multiple sclerosis lesion loads. Can J Neurol Sci 2005;32:205-12.
12. Wattjes MP, Harzheim M, Kuhl CK, Gieseke J, Schmidt S, Klotz L et al. Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic mr imaging criteria for multiple sclerosis? AJNR Am J Neuroradiol 2006;27:1794-8.
13. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
15. Wolansky LJ, Finden SG, Chang R, Conigliari M, Lee HJ, Shaderowsky PD et al. Gadoteridol in multiple sclerosis patients. A comparison of single and triple dose with immediate vs. delayed imaging. Clin Imaging 1998;22:385-92.
16. Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72:1976-83.